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Intercalation of drugs into assembled DNA systems offers versatile new mechanisms for controlled drug 
delivery. However, current systems are becoming increasingly complex, reducing the practicality of 
large scale production. Here, we demonstrate a more pragmatic approach where a short DNA sequence 
was modified with poly[ethylene glycol] (PEG) of various lengths at both 5′-termini to provide serum 
stability and compatibility. The anti-cancer drug doxorubicin was physically loaded into two designed 
binding sites on the dsODN. The polymer conjugation improved the stability of the dsODN towards 
serum nucleases while its doxorubicin binding affinity was unaffected by the presence of the polymers.  
We examined the effects of polymer size on the dsODN carrier characteristics and studied the resulting 
DOX@DNA–PEG systems with respect to cytotoxicity, cellular uptake and localization in A549 and 
MCF7 cell lines. For the A549 cell line the DOX@DNA-PEG1900 exhibited the best dose response of 
the conjugates while DOX@DNA-PEG550 was the least potent. In MCF-7, a more doxorubicin 
sensitive cell line, all conjugates exhibited similar dose response to that of the free drug. Confocal 
microscopy analysis of doxorubicin localization shows that conjugates successfully deliver doxorubicin 
to the cell nucleus and also the lysosome. These data provide a valuable insight into the complexities of 
designing an oligonucleotide based drug delivery system and highlight some practical issues that need to 
be considered when doing so.
  
INTRODUCTION 
In recent decades DNA-based materials have revolutionized the scope and complexity of 
nanomaterials that can be produced. Exploiting the specificity of Watson-Crick base pairing has 
produced complex dynamic structures such as molecular computers,(1) motors,(2) nanoreactors,(3) as 
well as sensors and diagnostics.(4-10) More recently, the ability of certain drugs to intercalate within the 
DNA double helix and form strong physical complexes has been utilized to form physical prodrugs for 
cytotoxics. Farokhzad et al. first demonstrated that a DNA aptamer could be loaded with doxorubicin 
(DOX), allowing targeted uptake into cells presenting the aptamer target.(11) This was extended to 
aptamer-targeted quantum dots(12) and polymer particles(13) allowing the addition of detection and 
delivery. Dabrowiak et al. have demonstrated several systems based upon gold nanoparticles (AuNPs) 
coated with DNA. Both DOX and actinomycin D (ActD) were intercalated into the helix, and targeting 
was achieved by introduction of folic acid onto one of the DNA strands.(14-16) “DNA origami” has 
also been used for intercalated delivery. Ahn et al. have demonstrated that a DNA tetrahedron, formed 
by annealing 4 strands, can be used to deliver DOX to cells, overcoming resistance in a multi-drug 
resistant cell line.(17) Leong et al. have used similar tetrahedra, decorated with AuNPs and loaded with 
ActD, for theranostic delivery to bacteria.(18) Högberg et al. have taken the origami approach a step 
further and designed large DNA bundles that can twist upon intercalation of DOX. Drug release 
kinetics, and thus cytotoxicity, can be modulated by varying the induced twist.(19) 
Although these systems have demonstrated the feasibility of using DNA intercalation as a drug 
delivery mechanism, problems still remain. First, none have the shielding components required to 
prevent degradation and reduce potential immunogenic interactions in vivo, although some of the non-
natural DNA conformations have been shown to be resistant to degradation.(20) Second, the systems 
being developed are displaying increasing complexity, in one case requiring over 200 short DNA 
“staples” to hold the drug delivery system together, where each of which has to be synthesized and 
purified. PEG polymers have been extensively used to improve the pharmacokinetics of biologics.(21) 
Despite recent concerns about potential immunogenicity of PEG,(22) this remains controversial,(23) 
and they are still the polymer of choice for in vivo applications.  
Herein we describe a more pragmatic approach to intercalating drug delivery. A simple, short, double 
stranded DNA was assembled from complementary oligonucleotides, modified with poly(ethylene 
glycol) (PEG) at the both 5′ positions. The effects of PEG polymer size on the ODN carrier delivery 
characteristics were examined. DOX was physically conjugated by intercalation into a pair of binding 
sites designed into the oligonucleotide sequence forming the DOX@DNA–PEG delivery system (Fig. 
1).  
 
Figure 1. Schematic representation of intercalating DOX@DNA delivery system described herein. 
RESULTS AND DISCUSSION 
Synthesis and analysis of PEG-DNA conjugates. 
PEG–DNA conjugates were synthesized in a similar manner to that described previously.(10) 
Polyethylene glycol monomethyl ether (mPEG, Mn 550, 1900 and 5000 Da) were activated with N,N-
disuccinimidyl carbonate to form amino-reactive mPEG-succinimidyl carbonates (PEG-SC). The PEG-
SCs were subsequently conjugated to 5′-aminohexyl modified single-stranded oligonucleotides to form 
a small library of PEG–ssDNA conjugates with 3 different PEG lengths, and consisting of two 
complementary DNA sequences (Oligo A: TAA CAG GAT TAG CAG AGC GAG G and Oligo B: 
CCT CGC TCT GCT AAT CCT GTT A). Conjugates were purified by semi-preparative HPLC with 
typical isolated yields of 50–80% independent of mPEG length. HPLC and PAGE analysis (Fig. 2A and 
S1) confirmed no residual unmodified oligonucleotides in any of the conjugate samples. Molecular 
masses from MALDI-ToF mass spectrometry were generally in good agreement with theoretical values, 
however slight deviation from theoretical values was observed. This is not unexpected as mPEG is a 
disperse polymer and some molecular weight enrichment is likely to occur during HPLC purification i.e. 
polymer fractionation. 
Lyophilized conjugates were dissolved in DNase-free annealing buffer and hybridized with the 
appropriate complementary strands (e.g. PEG550-A and PEG550-B) to form dsDNA conjugates with 
mPEG chains at both 5′-termini. Consequently, a series of three PEG DNA conjugates was produced, 
DNA–PEG550, DNA–PEG1900 and DNA–PEG5K, as well the unPEGylated, “unmodified” DNA. 
After annealing, the conjugates were analyzed by PAGE to ensure that no single stranded ODNs were 
remaining after the annealing (Fig. 2A and Fig S1A). PAGE analysis revealed that the PEG-ODNs had 
successfully formed the double stranded structures. Weak high molecular weight bands were observed 
for the single strands in all of the gels which arose from self-association of the unhybridized strands 
under the non-denaturing conditions. 
Stability of DNA–PEG conjugates. 
To determine the effect of PEG on DNA stability towards nucleases, DNA–PEG conjugates and 
unmodified DNA were incubated in presence of fetal calf serum. The conditions were chosen to mimic 
as closely as possible those used for later in vitro experiments to ensure that any effects that arose from 
differential degradation could be accounted for. The samples were analyzed by native PAGE and 
individual band intensity estimated using image analysis software. The band intensity of each conjugate 
at the start of the experiment (0 hours) was set as 100%. All DNA–PEG conjugates were stable for the 
duration of the experiment with 80–90% remaining after 72 h. Conversely, the unmodified DNA had 
completely degraded after 72 h and was reduced to approximately 40% after 48 h (Fig. 2B and S2). The 
conjugation of the PEG polymers to each terminus of the DNA therefore improved its stability 
significantly and provided protection against the nucleases. However, no effect of polymer molecular 
weight on stability was observed under these conditions. 
 
Figure 2. A. PAGE analysis of PEG5K-oligos and DNA–PEG5K conjugates. Lanes L-R: (1) IDT 
Ladder 10/60, (2) Oligo A, (3) Oligo B, (4) dsDNA, (5) PEG5K-A, (6) PEG5K-B, (7) DNA–PEG5K. B. 
Stability of DNA conjugates in serum. C. Affinity of doxorubicin for DNA–PEG1900 carriers. 
Fluorescence spectra of DOX with increasing ODN concentrations with corresponding Hill plots and 
calculated Kd values. 
Doxorubicin-loading and affinity 
The affinity of doxorubicin (DOX) to the DNA carriers was examined in order to determine the 
binding of the drug and if this was affected by PEGylation. Doxorubicin binds preferentially to 5′-GC-3′ 
and 5′-CG-3′ double stranded sequences,(24) thus it is expected that the sequence used here would have 
two preferential binding sites. Affinity measurements were performed by a previously established 
fluorescence quenching protocol.(11) The fluorescence of doxorubicin was plotted as a function of the 
oligonucleotide concentration to produce a Hill plot from which dissociation constants (Kd) were 
calculated (Fig. 2C and S3). Comparison of the calculated Kd values showed no difference beyond 
experimental error between the PEGylated and non-PEGylated DNA, with all being 200 ± 60 nM. 
In vitro cytotoxicity studies of DNA–PEG and DOX@DNA–PEG conjugates 
DNA conjugates promote cell proliferation: To determine if the DNA–PEG conjugates were 
capable of delivering DOX they were assessed in vitro in A549 cells (lung adenocarcinoma epithelial 
cells). Carriers were loaded at a 1/10 (w/w) with DOX based on their oligonucleotide content (i.e. 1 mg 
DOX per 10 mg of ODN) forming the DOX@DNA–PEG conjugates. Cells were incubated with free 
DOX, DOX@DNA–PEG and empty DNA–PEG carriers for 72 h. DOX concentrations ranged from 
0.15 nM–10 μM and were maintained across groups. For the unloaded conjugates the concentrations 
were matched to the oligonucleotide concentrations used in the DOX@DNA–PEG group. Metabolic 
activity was assessed by MTT assay, untreated cells were normalized as 100% metabolic activity. 
As expected, free DOX resulted in complete suppression of metabolic activity at higher 
concentrations (≳1 μM), with a calculated IC50 of 89 nM (95% CI 57–131 nM, Fig. 3A). However, for 
DOX@DNA–PEG conjugates complete suppression was not seen even at very high concentrations of 
DOX (10 μM), with approximately 30% metabolic activity remaining compared to untreated cells (Fig. 
3B and S3). Although intercalation of the DOX within a carrier is expected to affect cell entry, and thus 
cytotoxicity, this should be compensated for at the higher concentrations. When considered with the 
effect of the unloaded DNA–PEG (Fig. 3C) it is clear that the carriers alone promote metabolic 
activity/cell growth, and this promotion is also dose dependent. Visual inspection during the course of 
the experiment revealed that the cell density increased as a function of DNA concentration which was in 
an agreement with the MTT results. It has previously been shown that pyrimidine nucleosides are 
growth promoting when they are present in media at a concentration of 1µg/mL with endothelial cells. 
(22) Cells which are proliferating rapidly require a high rate of DNA synthesis. For those cells the rate 
of DNA synthesis can become the growth limiting factor. To administer 10 µM DOX, 58 µg/mL of the 
dsODN carrier was required. The proliferation of the A549 cell line was thus promoted by degradation 
of the dsODN carrier and subsequent release of free nucleosides. The dsODN carrier was not shown to 
promote the proliferation of a MCF-7 breast cancer cell line. 
 
Figure 3. Cytotoxicity of A. doxorubicin; B. DOX@DNA–PEG1900; and C. DNA–PEG1900 dsODN 
in the A549 cell line. 
Cytotoxicity of DOX@DNA–PEG and DNA–PEG. To counteract enhanced cell proliferation in the 
presence of oligonucleotide carriers further in vitro studies were performed in media supplemented with 
free nucleosides (A, C, G and T; 10 µg/mL each) for both cell lines. Cytotoxicity experiments were 
performed with A549 cells as before. With the addition of free nucleosides to the media no 
enhancement in cell proliferation was observed in the presence of unloaded dsODN carriers when 
compared to untreated cells (Fig. S4). For free DOX complete suppression of metabolic activity was 
observed at high concentrations as before (Fig 4). However, the calculated IC50 value increased to 124 
nM (95% CI 102–151 nM) indicating that a higher dose of DOX is required to inhibit cell growth in the 
presence of nucleosides, further supporting our previous conclusions. The half maximal inhibitory 
concentration (IC50) is derived as the mid-point between the maximum and minimum of the dose 
response curve. However, since the maximal inhibition response varies between DOX@DNA carriers 
and to that of the free drug direct IC50 comparison between the groups was difficult. Consequently, 
IC50 values were also calculated by interpolation of the fitted curve at 50% viability. In the case of free 
DOX, where the maximum inhibition nears 100%, this has little effect on the calculated IC50 (126 nM 
c.f. 124 nM) however it provides a more realistic value for the DOX@DNA samples. Values calculated 
by both methods are contained with Table 1. 
 
Table 1. Cytotoxicity data for doxorubicin and DOX@DNA complexes in A549 and MCF7 cells 
  Curve Fit
a
 Interpolated
b
  
Treatment Cells IC50 (nM)
a
 
95% CI 
(nM) 
IC50 (nM)
a
 
95% CI 
(nM) 
Vialmax 
(%±SD)
c 
DOX A549 124 102–151 126 109–144 4.2±0.3 
DOX@DNA A549 67 43–104 132 104–165 19.3±2.0 
DOX@DNA–
PEG550 
A549 167 105–265 
541 
411–718 30.8±7.0 
DOX@DNA–
PEG1900 
A549 35 26–48 
122 
98–151 27.3±1.8 
DOX@DNA–
PEG5K 
A549 66 47–92 
232 
189–282 28.0±1.9 
DOX MCF7 19 12–29 27 20–37 6.4±0.6 
DOX@DNA MCF7 31 19–52 37 27–49 3.4±0.5 
DOX@DNA–
PEG550 
MCF7 32 21–50 
40 
31–50 9.8±1.2 
DOX@DNA–
PEG1900 
MCF7 11 7–17 
19 
14–26 11.5±1.7 
DOX@DNA–
PEG5K 
MCF7 10 8–15 
17 
13–24 4.2±0.3 
a
 Calculated using the 4-parameter variable slope log(inhibitor) vs response model in Graphpad Prism 
6.0. As incomplete inhibition was achieved for some treatments these values are relative to the achieved 
maximum inhibition. 
b
 Calculated by interpolation of the fitted curve at 50% relative metabolic activity. 
c
 Viability at maximum DOX concentration. 
 
For non-PEGylated DOX@DNA, an IC50 of 132 nM (95% CI 104–165 nM) is comparable to that of 
free DOX. This is not unexpected considering that the unshielded DNA is readily degraded in the 
presence of serum and this is likely to be exacerbated in the presence of cells or if internalized. 
However, even at the highest non-PEGylated DOX@DNA concentration (1 μM) cell viability remains 
at ~20% compared to the untreated control. For the DOX@DNA–PEG samples IC50 values are strongly 
dependent on the molecular weight of the shielding polymer. DOX@DNA– PEG5K and DOX@DNA–
PEG550, with IC50s of 232 nM (95% CI 189–282) and 541 nM (95% CI 411–718) respectively, are 
approximately 2- and 4-fold less toxic than DOX@DNA. DOX@DNA–PEG1900 maintains an IC50 
similar to that of DOX@DNA and free drug with an IC50 of 122 nM (95% CI 98–151). The 
DOX@DNA–PEG conjugates all exhibited dose saturation at highest DOX@DNA concentrations and 
inhibition was limited to approximately 70% in comparison to 95% inhibition for the free drug.  
In vitro studies were extended to a MCF7 cell line (breast adenocarcinoma epithelial cells) to 
determine if the limiting toxicity was cell line specific. MCF7 cells were more sensitive to DOX with an 
IC50 of 27 nM (95% CI 20–37) for free drug and all systems were capable of ~90–95% inhibition at the 
highest concentrations. The greater sensitivity results in less pronounced effects seen with polymer 
molecular weight, with little variation between treatments, particularly when the large confidence 
intervals are considered. 
 
Figure 4. Cytotoxicity of DOX@DNA–PEG in A549 and MCF-7 cell lines. Cells were cultured in the 
presence of free nucleosides. Samples (black) are as labelled. Free DOX (red) is shown for comparison. 
Lines are calculated four-parameter logistic fits. 
Confocal microscopy analysis of cells treated with DOX@DNA 
DOX@DNA systems display cell line dependent localization. To further understand the 
cytotoxicity data DOX@DNA systems were studied by confocal microscopy in A549 and MCF7 cells. 
Cells were incubated with DOX@DNA carriers and free DOX and the localization studied at various 
time points using the inherent fluorescence of the drug for detection. Due to sensitivity requirements the 
drug concentration was fixed at 3 μM in all cases. After 3 hours (Fig. 5), free DOX showed intense 
staining in the nucleus in both cell lines indicating rapid uptake, while in all DOX@DNA nuclear 
staining was considerably less intense. DOX@DNA samples contain punctate regions within the 
cytoplasm and in the perinuclear region; this was particularly pronounced in A549 cells. This 
demonstrates that dsODN are readily internalized into both A549 and MCF7 cells, albeit at lower levels 
than free drug, and allow trafficking into the target organelle. By 18 hours (Fig. 6) nuclear staining in 
MCF7 cells remains intense for both free drug and dsODN-DNA while other conjugates have lower 
levels. In contrast A549 cells have lower levels of nuclear staining compared to MCF7 cells but retain 
staining in cytoplasmic regions for all DOX@DNA samples and free DOX. 
 
Figure 5. Cellular uptake DOX@DNA samples. Cells were incubated with doxorubicin loaded 
conjugates for 3 hours. Intrinsic doxorubicin fluorescence was visualized by confocal microscopy. Bar = 
20 µm. 
 
Figure 6. Cellular uptake DOX@DNA samples. Cells were incubated with doxorubicin loaded 
conjugates for 18 hours. Intrinsic doxorubicin fluorescence was visualized by confocal microscopy. Bar 
= 20 µm. 
Intracellular localization after 18 hours 
In order to investigate the intracellular localization of internalized DOX, cells were incubated for 18 
hours with free DOX or DOX@DNA and the lysosomal compartments were counterstained (Fig. 7 and 
S6 for non-merged images). In MCF7 cells intense doxorubicin staining was observed in the nucleus for 
all dsODN and free dox. Furthermore, punctate doxorubicin positive regions co-localized with the 
lysosomal marker. In contrast, A549 cells showed no detectable nuclear staining at 18 hours, even for 
free DOX, while retaining cytoplasmic doxorubicin positive lysosomal staining. This contrasts with the 
findings of the previous experiment (Fig. 6) where some low level signal was still detected in nucleus of 
A549 cells at 18 hours. However, due to the broad excitation/emission spectra of both doxorubicin and 
the lysosomal marker, the collection range and signal gain for doxorubicin had to be narrowed to 
prevent signal bleed through. The co-localization assay (Fig. 7) therefore only visualized the most 
intense regions of doxorubicin staining i.e. the punctate cytoplasmic regions. Lower levels of 
doxorubicin fluorescence may reflect increased efflux of doxorubicin from A549 cell nuclei in 
comparison to MCF7 cells which could explain the cell lines elevated resistance to the drug. Both cell 
lines have been shown to express multidrug resistance associated-proteins (MRP) which can limit the 
efficiency of chemotherapy.(25) Encapsulation of doxorubicin in dsODN allows the drug to traffic into 
the nucleus and lysosome however it does not alter the final destination of the doxorubicin nor prevent 
drug efflux. However, replacement of the oligonucleotide segment with one that exerts its own 
therapeutic effect, e.g. siRNA or T-oligos,(26, 27) may provide a synergistic effect. 
 Figure 7. Doxorubicin co-localizes with a lysosomal marker. MCF-7 and A549 cells  were incubated 
with DOX@DNA-PEG for 18 hours then counterstained for lysosomes with CytoPainter Lysosome 
Blue. Doxorubicin (red) and lysosomal (blue) staining was visualized by confocal microscopy. Arrows: 
areas of colocalization. Bar = 5 µm 
 
CONCLUSIONS 
We have described the synthesis and in vitro biological activity of a series of oligonucleotide-
based carriers for doxorubicin. Carriers were synthesized by conjugation of PEG to the 5' termini 
of ODN and hybridization by Watson-Crick base pairing. As expected, PEGylation was found to 
enhance stability to serum nucleases compared to an unPEGylated control. DOX was 
successfully bound to the carriers with high affinity (Kd ~200 nM) in all cases. 
 
Initial in vitro assays with A549 cells revealed that the carriers promoted cell growth compared 
to untreated control, with later experiments requiring supplementation with free nucleosides to 
enable comparison. Comparisons of the metabolic activity, uptake and localization of 
DOX@DNA systems in A549 and MCF7 cells demonstrated several differences. In MCF7 cells, 
metabolic activity and uptake were comparable to that of free DOX. Conversely, in A549 cell 
line DOX@DNA systems had a lesser effect on metabolic activity than free DOX with no 
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system able to achieve more than 70% inhibition. Uptake studies determined that DOX@DNA 
systems were taken up to a lower extent than free DOX, and that DOX levels in nuclei reduced 
with time in A549 cells compared to MCF7 cells 
Our findings highlight the issues that need to be addressed when designing and evaluating 
oligonucleotide based drug delivery systems. The vast difference observed between the two cell 
lines underlines the importance of adopting appropriate in vitro models early on and 
supplementing tissue culture medium with free nucleosides. Our results suggest that our PEG-
based system could be used to treat doxorubicin sensitive cancer cells in instances where adverse 
drug effects are limiting. The data derived from A549 cell line also accentuates the fact that 
PEGylated-dsODN system would be not suitable to treat drug resistance cells, in those 
circumstances amphiphilic polymers and known inhibitors of multidrug resistance protein (MRP) 
should be considered instead.(28, 29) We are currently evaluating alternative dsODN-derived 
systems to address this issue of drug resistance. 
MATERIALS AND METHODS 
Materials 
All oligonucleotides (HPLC purified) were purchased from Biomers.net GmbH (Ulm, 
Germany) and used without further purification. MCF-7 and A549 cell lines were received from 
CRN NCI-60 cell bank. 
Polyethylene glycol monomethyl ether (mPEG, Mn 5000, 1900 and 550 Da) were purchased 
from Polysciences Inc. CytoPainter lysosomal staining kit blue fluorescence was purchased from 
Abcam. N,N′-Disuccinimidyl carbonate (DSC, ≥95.0%), triethylamine (Et3N, ≥99%), thiazolyl 
blue tetrazolium bromide (MTT, 98%), water (BPC grade), diammonium hydrogen citrate 
(DAHC, ≥99%), Stains-All (95%), 3-hydroxypicolinic acid (3-HPA, (≥99%)),  methylene blue 
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hydrate (>97%), tris-borate-EDTA buffer (TBE, 10× concentrate), ammonium persulfate 
(≥98%), N,N,N′,N′-tetramethylethylenediamine (TEMED, 99%), ethylenediaminetetraacetic acid 
disodium salt (EDTA, >99%), glycerol anhydrous (Fluka), bromophenol blue solution (0.04  
wt% H2O), acrylamide:N,N′-methylenebisacrylamide (29:1) 40% solution and Dulbecco’s PBS 
(Modified, without calcium chloride and magnesium chloride) were purchased from Sigma 
Aldrich. 
All other solvents and reagents were of analytical or HPLC grade and purchased from Sigma 
Aldrich unless otherwise specified. 
NMR Spectroscopy 
NMR spectra were recorded on a Bruker Avance 400 spectrometer at 400.13 MHz (
1
H) and 
100.62 MHz (
13
C, 
1
H decoupled at 400.13 MHz) in chloroform-d. All chemical shifts are 
reported in ppm relative to the signal for tetramethylsilane. 
HPLC analysis and purification of DNA strands 
Reverse phase high performance liquid chromatography (RP-HPLC) was performed on a 
Shimadzu Prominence UPLC system fitted with a DGU-20A5 degasser, LC-20AD low-pressure 
gradient pump, CBM-20A LITE system controller, SIL-20A autosampler and an SPD-M20A 
diode array detector. Analytical separations were performed on a Phenomenex Clarity 3 μm 
Oligo-RP C18 column (4.6×50 mm) with a gradient of MeOH (10–70% for PEG5K and 
PEG1900 ODNs and 10–50% for PEG550 ODNs over 20 min) in 0.1 M triethylammonium 
acetate (TEAA, pH 7.5)/MeCN (95/5) as the mobile phase at a flow rate of 1.0 mL/min. Semi-
preparative separations were performed on a Phenomenex Clarity 3 μm Oligo-RP C18 column 
(10×50 mm) under the same conditions at a flow rate of 5.0 mL/min. 
MALDI-ToF Mass Spectrometry 
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Matrix-assisted laser desorption/ionization time-of flight (MALDI-ToF) mass spectrometry 
was performed on a Bruker MALDI-ToF Ultra Flex III spectrometer operated in linear, positive 
ion mode. 3-HPA containing DAHC was used as the matrix for oligonucleotide analysis. Briefly, 
a saturated solution of 3-HPA (50 mg/mL) was prepared by adding 25 µg of 3-HPA to 500 µL of 
50% MeCN/water. 25 µL of DAHC solution (100 mg/mL) was added to 225 µL of the 3-HPA 
solution, to give a final DAHC concentration of 10 mg/mL. ODN solutions were desalted prior 
to mixing with matrix using C18 Ziptips. Equal volumes of matrix solution and ODN solution 
(0.2 mM) were mixed and 2 µL of the mixture was spotted onto the MALDI plate and allowed to 
dry. 
Polyacrylamide Gel Electrophoresis 
Polyacrylamide gel electrophoresis (PAGE) analysis was performed at 160 mV using a 15% 
acrylamide running gel. Native gels were prepared using acrylamide–bis-acrylamide (29:1) and 
TBE (Tris-borate-EDTA) solutions. Samples were prepared by dilution in native loading buffer 
containing glycerol and bromophenol blue. 5 µg of oligonucleotide was loaded per well. IDT 
Oligo Length Standard 10/60 was used a size marker for the gels. The oligonucleotide/polymer 
bands were visualized using methylene blue staining. 
Synthesis of α-methoxy-ω-succinimidyl carbonate poly[ethylene glycol] (mPEG-SC) 
mPEG550-SC. mPEG (Mn 550 Da, 1.39 g, 2.5 mmol) was dried by azeotropic distillation with 
toluene. The residue was dissolved in THF (100 mL) and the solution cooled to 0°C with an ice 
bath. DSC (1.89 g, 7.4 mmol) and TEA (0.745 g, 7.4 mmol) were added and the solution allowed 
to warm to room temperature then stirred overnight (16 h). The resulting suspension was filtered 
and volatiles removed under reduced pressure. The residue was dissolved in toluene and any 
insoluble material removed by filtration. Toluene was removed under reduced pressure and the 
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residue redissolved in chloroform. In order to remove any unreacted DSC Wang resin/TEA was 
added to the solution and allowed to react overnight. The resin was removed by centrifugation 
and the supernatant was washed with 0.1 M HCl. The organic layer was dried over MgSO4, 
filtered and volatiles removed under reduced pressure. The product was dried under vacuum and 
isolated as yellowish oil (400 mg, 20% yield). 
1H NMR (CDCl3, 400 MHz): δ 4.49–4.47 (t, 2H), 3.82–3.56 (m, 50H), 3.40 (s, 3H), 2.86 (s, 
4H). 
mPEG1900-SC. mPEG (Mn 1900 Da, 3g, 1.6 mmol) was dried by azeotropic distillation with 
toluene. The residue was dissolved in MeCN (70 mL) and the solution cooled to 0 C with an ice 
bath. DSC (1.01 g, 4 mmol) and TEA (0.4 g, 4 mmol) were added and the solution allowed to 
warm to room temperature then stirred overnight (16 h). The resulting suspension was filtered 
and concentrated under reduced pressure. The crude product was precipitated into Et2O and 
collected by vacuum filtration. The product was purified by twice re-dissolving in CHCl3 and 
precipitating into Et2O. After drying under vacuum the product was recovered as white powder 
(1.5 g, 47% yield).  
1
H NMR (CDCl3, 400 MHz): δ 4.49–4.47 (t, 2H), 3.84–3.48 (m, 206H), 3.40 (s, 3H), 2.86 (s, 
4H). 
mPEG5000-SC. mPEG5000-SC was synthesized by the same protocol as mPEG1900-SC 
starting for mPEG (Mn 5 kDa). Isolated 7 g, 68% yield. 
1
H NMR (CDCl3, 400 MHz): δ 4.49–4.47 (t, 2H), 3.85–3.48 (m, 522H), 3.40 (s, 3H), 2.86 (s, 
4H).  
General procedure for the synthesis of PEGylated oligonucleotides 
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PEGylated oligonucleotides were synthesized as previously described.(10) Specific reaction 
conditions are detailed in table 2. Briefly, 5′-aminohexyl oligonucleotide (1 eq.) was dissolved in 
DPBS to a concentration of 2.5 mg/mL. A solution of mPEG-SC (5 eq.) was added with gentle 
agitation and the reaction allowed to proceed for up to 72 h. Conversion was monitored by 
HPLC and additional mPEG-SC added if required. PEGylated oligonucleotides were purified by 
semi-preparative HPLC and lyophilized. Lyophilized materials were redissolved in DNase free 
water and concentration determined by measurement of optical density at 260 nm (1 OD = 20 
μg/mL). Solutions were then aliquoted and lyophilized before storage at -20 °C. 
Table 2. Conditions and analytical data for the PEGylation of oligonucleotides 
Oligo
a 
PEG Equiv. Solvent
b
 Yield
c 
MALDI
d
 
A 550 5 THF 66 7729/7633 
B 550 5 THF 54 7484/7386 
A 1900 5 DMSO 75 9079/9076 
B 1900 5 THF 56 8834/9271 
A 5000 5 DMSO 54 12189/12189 
B 5000 6.7 DMSO 84 11934/12006 
a
 Sequences. Oligo A: TAA CAG GAT TAG CAG AGC GAG G; Oligo B: CCT CGC TCT 
GCT AAT CCT GTT A. 
b
 for dissolution of mPEG-SC. 
c
 calculated from measured OD values. 
d
 
theoretical/found. 
Hybridization of DNA strands 
Strands were hybridized in annealing buffer which consisted of 10 mM Tris, 50 mM NaCl and 
1 mM EDTA pH 7.5. For the hybridisation the strands were mixed in equimolar quantities to 
give a final concentration of 75 µM of each strand and placed in a water bath at 95 °C for 5 
minutes. The water bath was then turned off and allowed to cool slowly to room temperature. 
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Annealed strands were desalted using a PD SpinTrap G-25 column (GE Healthcare) and 
oligonucleotide concentration determined by optical density @ 260 nm (1 OD = 30 ug/mL). 
Annealing was verified using PAGE gel under non-denaturing conditions. Solutions were 
aliquoted, lyophilized and stored at -20 °C until needed. 
Drug loading of DNA carriers 
Doxorubicin HCl (Dox HCl) (1 mg) was dissolved in UHQ water (1 mL). The solution was 
filtered through a 0.22 µm PES syringe filter and stored at 4 °C until use. DNA carriers were 
dissolved in sterile DPBS. Dox HCl was added to the DNA solution in order to achieve a 10% 
(w/w) Dox HCl to DNA drug loading. The DOX@DNA complexes were allowed to form for 30 
min. and used without further purification. For in vitro experiments the DOX@DNA complexes 
were diluted 25-fold with media to a DOX concentration of 10 µM (5.8 µg/mL of DOX, 58 
µg/mL ODN). 
Stability of oligonucleotides 
DOX@DNA systems were incubated at an oligonucleotide concentration of 0.63 µg/mL in 
DPBS containing 10% Fetal Calf Serum (FCS). Solutions were incubated at 37 C with mild 
agitation. At each time point (0, 24, 48, 72 h) a sample (10 μL) was removed, flash frozen in liq. 
N2, and stored at -20 °C until analysis by PAGE.  The samples were diluted with 10 µL of 
loading buffer and 10 µL of the diluted sample loaded per well. PAGE was carried out at 160 
mV using a 15% acrylamide gel. The oligonucleotide/polymer bands were visualized using 
methylene blue. Intensity of gel bands was estimated by image analysis using Scion Image 
(Macro: Gelplot2). 
Affinity of doxorubicin HCl to hybridized oligonucleotide strands 
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A fluorescence spectroscopy method(11) was used to assess the binding affinity of DOX for 
DNA systems. The assay was performed with a constant DOX concentration (1.5 µM) while 
DNA carrier was titrated from 0 to 15 molar (DNA concentrations: 15, 10, 7.5, 4.5, 1.5, 0.75, 
0.45, 0.15, 0.045 , 0.015, 0.005 and 0 µM). A Hill plot was used to determine the binding affinity 
of the double stranded oligonucleotide sequence to doxorubicin HCl (Y: (F0-F), X: 
Concentration ODN µM). All analyses were performed in Graphpad Prism 6.0. 
In vitro assays 
General. The MCF-7 cells were grown in standard T75 flasks. A549 cells were grown in T75 
flasks treated for optimal attachment (Corning T75 Cat no 430641). Both cell lines were grown 
in Minimum Essential Medium Eagle (MEM) media containing 4 mM L-Glutamine, 
Penicillin/Streptomycin and 10 % FCS. The media was supplemented with nucleosides (G, C, T, 
A) at the later stages of the cell work, each nucleoside was added at a final concentration of 10 
µg/L. 
Cytotoxicity Assays. Cells were allowed to reach confluence in the T75 flasks before being 
seeded onto 96-well plates. Cells were seeded at 5×10
3
 cells/well for both cell lines (100 µL, 
5×10
4
 cells/mL). Cells were allowed to attach for 24 hours before the media was removed and 
replaced with 100 µL of media containing the appropriate DOX concentration. For experiments 
with carrier alone, an equivalent concentration of DNA (without drug) was used. 6 wells were 
used for each concentration. Cells were treated for 72 hours before metabolic activity was 
determined using an MTT assay. MTT solution (10 µL of 5 mg/mL) in media was added to each 
well and allowed to develop for 75 minutes. The media was then carefully aspirated and wells 
washed with PBS (100 μL). The formazan crystals were finally dissolved by adding DMSO (100 
µL) to each well. The plate was read using a Tecan M200 platereader at 562 nm and the MTT 
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response compared to untreated cells. Untreated cells were normalized as 100% metabolic 
activity. 
Toxicity curves were fitted with Graphpad Prism 6.0 using the 4-parameter variable slope 
log(inhibitor) vs response model. Due to incomplete inhibition IC50 calculated are considered as 
relative. Real IC50 values were calculated by interpolation of the fitted curve within the same 
software. 
Confocal Microscopy 
Cells were seeded on Nunc LabTekII coverglass 8 well slides at 20,000 cells/well and 
incubated overnight. Conjugates were loaded with drug as described above and added to cells at 
a final doxorubicin concentration of 3µM. After the required incubation time cells were fixed in 
cold 4 % paraformalydehyde in PBS for 10 minutes. Samples were stored at 4 °C and imaged by 
Laser Scanning Confocal Microscopy (LSCM) within 24 hours. Settings were excitation 532 nm 
laser, emission 552-654 nm. Lysosomal staining was conducted using CytoPainter Lysosomal 
staining kit – blue (Abcam, ab112135) following the manufacturer’s instructions with an 
incubation time of 20 minutes. Cells were imaged immediately by LSCM using settings 
excitation 405 nm, emission 430-480 nm and excitation 532 nm, emission 553-672. 
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